Yu Guopan相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML.

单细胞分析揭示了TP53突变型AML中重新编程的层级结构和被破坏的免疫基质生态系统。

期刊:Experimental Hematology & Oncology

影响因子:13.5

doi:10.1186/s40164-026-00751-x

Qiu Guo, Yin Zhao, Lu Xiaoyue, Xue Rongtao, Tang Shengjiao, Zhou Cuiyan, Huang Xueping, Fan Menglin, Ai Yanjia, Xiang Guangmei, Wang Luting, Yu Sijian, Yu Guopan, Shi Pengcheng, Zhao Ke, Liu Hui, Zhang Yu, Shan Meng, Xuan Li, Xiong Jing, Xu Xi, Liu Qifa, Wang Yu

细胞生物学

免疫/内分泌

发表日期：2026

文献求助收藏

Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial

地西他滨联合减低强度预处理方案用于接受异基因造血干细胞移植的处于复合完全缓解期的老年急性髓系白血病患者：一项多中心、单臂 II 期试验

期刊:The Lancet Regional Health Western Pacific

影响因子:8.1

doi:10.1016/j.lanwpc.2025.101664

Liu, Qifa; Hu, Zhongli; Xu, Na; Jiang, Yirong; Fan, Zhiping; Huang, Fen; Lin, Ren; Jin, Hua; Zeng, Yunxin; He, Hai; Zhu, Ping; Yu, Guopan; Shi, Pengcheng; Sun, Ruijuan; Xu, Xiaojun; Li, Zhangkun; Zhang, Yu; Sun, Jing; Wang, Yu; Xuan, Li

发育与干细胞

细胞生物学

发表日期：2025

文献求助收藏

Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia

在CLAG方案中加入维奈托克可能改善复发/难治性急性髓系白血病患者的预后。

期刊:Therapeutic Advances in Hematology

影响因子:3.1

doi:10.1177/20406207251319603

Zhang, Yu; Yin, Zhao; Yao, Zurong; Xu, Dan; Jiang, Xuejie; Nie, Xiaqi; Chen, Dandan; Zhou, Hongsheng; Shi, Pengcheng; Liu, Hui; Liu, Qifa; Yu, Guopan

发表日期：2025

文献求助收藏

Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy

临床和遗传特征可预测接受维奈托克治疗的FLT3突变急性髓系白血病患者的预后

期刊:Cancer Medicine

影响因子:3.1

doi:10.1002/cam4.6885

Weng, Guangyang; Huang, Jingya; An, Na; Zhang, Yu; Yu, Guopan; Sun, Zhiqiang; Lin, Dongjun; Deng, Lan; Liang, Xinquan; Xiao, Jie; Zhang, Hongyu; Guo, Ziwen; He, Xin; Jin, Hua; Liu, Qifa; Du, Xin

发表日期：2024

文献求助收藏

Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission

可测量的残留病灶联合CD19对成人t(8;21)急性髓系白血病首次完全缓解后治疗选择的影响

期刊:Cancer Medicine

影响因子:3.1

doi:10.1002/cam4.7074

Jia, Xi; Liao, Naying; Yu, Sijian; Li, Huan; Liu, Hui; Zhang, Haiyan; Xu, Jun; Yao, Yunqian; He, Han; Yu, Guopan; Liu, Qifa; Zhang, Yu; Shi, Pengcheng

发表日期：2024

文献求助收藏

Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia

高三尖杉酯碱可能有助于改善 AML1-ETO 阳性急性髓系白血病患者接受维奈托克和阿扎胞苷治疗的疗效。

期刊:Journal of Cancer Research and Clinical Oncology

影响因子:2.8

doi:10.1007/s00432-024-05861-9

Yin, Zhao; Yao, Zurong; Chen, Dandan; Zhang, Yu; Weng, Guangyang; Du, Xin; Lin, Dongjun; Xiao, Jie; Sun, Zhiqiang; Zhang, Hongyu; Liang, Xinquan; Guo, Ziwen; Zhao, Weihua; Xuan, Li; Jiang, Xuejie; Shi, Pengcheng; Liu, Qifa; Ping, Baohong; Yu, Guopan

发表日期：2024

文献求助收藏

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial

维奈托克联合阿扎胞苷和高三尖杉酯碱治疗复发/难治性急性髓系白血病：一项多中心 II 期试验

期刊:Journal of Hematology & Oncology

影响因子:40.4

doi:10.1186/s13045-023-01437-1

Jin, Hua; Zhang, Yu; Yu, Sijian; Du, Xin; Xu, Na; Shao, Ruoyang; Lin, Dongjun; Chen, Yanqiu; Xiao, Jie; Sun, Zhiqiang; Deng, Lan; Liang, Xinquan; Zhang, Hongyu; Guo, Ziwen; Dai, Min; Shi, Pengcheng; Huang, Fen; Fan, Zhiping; Yin, Zhao; Xuan, Li; Lin, Ren; Jiang, Xuejie; Yu, Guopan; Liu, Qifa

发表日期：2023

文献求助收藏

Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study

基于遗传学和微小残留病灶的风险导向治疗可改善AML1-ETO阳性AML患者的预后，一项多中心前瞻性队列研究

期刊:Blood Cancer Journal

影响因子:11.6

doi:10.1038/s41408-023-00941-4

Xu, Dan; Yang, Ying; Yin, Zhao; Tu, Sanfang; Nie, Danian; Li, Yiqing; Huang, Zhenqian; Sun, Qixin; Huang, Changfen; Nie, Xiaqi; Yao, Zurong; Shi, Pengcheng; Zhang, Yu; Jiang, Xuejie; Liu, Qifa; Yu, Guopan

发表日期：2023

文献求助收藏

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.

通过抑制自噬，同时靶向 FLT3 和 BTK 可以克服急性髓系白血病中 FLT3 抑制剂的耐药性

期刊:Haematologica

影响因子:7.9

doi:10.3324/haematol.2022.280884

Zhang Weiguo, Yu Guopan, Zhang Hongying, Basyal Mahesh, Ly Charlie, Yuan Bin, Ruvolo Vivian, Piya Sujan, Bhattacharya Seemana, Zhang Qi, Borthakur Gautam, Battula Venkata, Konopleva Marina, Rice William G, Andreeff Michael

发表日期：2023

文献求助收藏

Changing epidemiology, microbiology and mortality of bloodstream infections in patients with haematological malignancies before and during SARS-CoV-2 pandemic: a retrospective cohort study

SARS-CoV-2 大流行前后血液系统恶性肿瘤患者血流感染的流行病学、微生物学和死亡率变化：一项回顾性队列研究

期刊:BMJ Open

影响因子:2.3

doi:10.1136/bmjopen-2023-078510

Cai, Linjing; Chen, Huan; Wei, Yongqiang; Guo, Xutao; Zheng, Haiqing; Jiang, Xuejie; Zhang, Yu; Yu, Guopan; Dai, Min; Ye, Jieyu; Zhou, Hongsheng; Xu, Dan; Huang, Fen; Fan, Zhiping; Xu, Na; Shi, Pengcheng; Xuan, Li; Feng, Ru; Liu, Xiaoli; Sun, Jing; Liu, Qifa; Wei, Xiaolei

发表日期：2023

文献求助收藏